The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.
Boing Boing on MSN12d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Inquirer on MSN16d
Controlled drug Ketamine a lifeline for patients with severe depression in SingaporeSINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has in the last four years become a boon to scores of severely depressed ...
Kelsey Warren [email protected] 609 218 4053 Investor contact: Lauren Johnson [email protected] ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.
Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two ...
The bill does not include the cost of oral anti-depressants, which must accompany any Spravato course, and the talk therapy that doctors recommend. Patients usually have to continue on both ...
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback